

IBS-C Drugs-Asia Pacific Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/I7D0A363330MEN.html

Date: May 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: I7D0A363330MEN

Abstracts

Report Summary

IBS-C Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023

Main market players of IBS-C Drugs in Asia Pacific, with company and product introduction, position in the IBS-C Drugs market

Market status and development trend of IBS-C Drugs by types and applications Cost and profit status of IBS-C Drugs, and marketing status Market growth drivers and challenges

The report segments the Asia Pacific IBS-C Drugs market as:

Asia Pacific IBS-C Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia



Australia

Asia Pacific IBS-C Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other

Asia Pacific IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacies Retail Pharmacies Online Pharmacies

Asia Pacific IBS-C Drugs Market: Players Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):

Catalent Pharmaceuticals Solutions

Nestle

Abbott Laboratories

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Novartis Pharma Ag

Astellas Pharmaceuticals

Ardelyx, Inc

Synthetic Biologics, Inc.

Teva Pharmaceutical Industries

Bama-Geve, SLU

Ferring BV

Ironwood Pharmaceuticals, Inc.

Salix Pharmaceuticals Ltd

Norgine B.V

Prometheus Laboratories Inc

Actavis Nordic A/S

Albireo Pharma Inc



Yuhan Corp Astrazeneca Plc The Menarini Group Ono Pharmaceutical Co., Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF IBS-C DRUGS

- 1.1 Definition of IBS-C Drugs in This Report
- 1.2 Commercial Types of IBS-C Drugs
 - 1.2.1 Linaclotide
 - 1.2.2 Lubiprostone
 - 1.2.3 Osmotic Laxatives
 - 1.2.4 Stimulant Laxatives
 - 1.2.5 Other
- 1.3 Downstream Application of IBS-C Drugs
 - 1.3.1 Hospital Pharmacies
 - 1.3.2 Retail Pharmacies
- 1.3.3 Online Pharmacies
- 1.4 Development History of IBS-C Drugs
- 1.5 Market Status and Trend of IBS-C Drugs 2013-2023
 - 1.5.1 China IBS-C Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023

CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of IBS-C Drugs in China 2013-2017
- 2.2 Consumption Market of IBS-C Drugs in China by Regions
 - 2.2.1 Consumption Volume of IBS-C Drugs in China by Regions
 - 2.2.2 Revenue of IBS-C Drugs in China by Regions
- 2.3 Market Analysis of IBS-C Drugs in China by Regions
- 2.3.1 Market Analysis of IBS-C Drugs in North China 2013-2017
- 2.3.2 Market Analysis of IBS-C Drugs in Northeast China 2013-2017
- 2.3.3 Market Analysis of IBS-C Drugs in East China 2013-2017
- 2.3.4 Market Analysis of IBS-C Drugs in Central & South China 2013-2017
- 2.3.5 Market Analysis of IBS-C Drugs in Southwest China 2013-2017
- 2.3.6 Market Analysis of IBS-C Drugs in Northwest China 2013-2017
- 2.4 Market Development Forecast of IBS-C Drugs in China 2018-2023
 - 2.4.1 Market Development Forecast of IBS-C Drugs in China 2018-2023
 - 2.4.2 Market Development Forecast of IBS-C Drugs by Regions 2018-2023

CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES



- 3.1 Whole China Market Status by Types
 - 3.1.1 Consumption Volume of IBS-C Drugs in China by Types
 - 3.1.2 Revenue of IBS-C Drugs in China by Types
- 3.2 China Market Status by Types in Major Countries
- 3.2.1 Market Status by Types in North China
- 3.2.2 Market Status by Types in Northeast China
- 3.2.3 Market Status by Types in East China
- 3.2.4 Market Status by Types in Central & South China
- 3.2.5 Market Status by Types in Southwest China
- 3.2.6 Market Status by Types in Northwest China
- 3.3 Market Forecast of IBS-C Drugs in China by Types

CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of IBS-C Drugs in China by Downstream Industry
- 4.2 Demand Volume of IBS-C Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of IBS-C Drugs by Downstream Industry in North China
- 4.2.2 Demand Volume of IBS-C Drugs by Downstream Industry in Northeast China
- 4.2.3 Demand Volume of IBS-C Drugs by Downstream Industry in East China
- 4.2.4 Demand Volume of IBS-C Drugs by Downstream Industry in Central & South China
- 4.2.5 Demand Volume of IBS-C Drugs by Downstream Industry in Southwest China
- 4.2.6 Demand Volume of IBS-C Drugs by Downstream Industry in Northwest China
- 4.3 Market Forecast of IBS-C Drugs in China by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS

- 5.1 China Economy Situation and Trend Overview
- 5.2 IBS-C Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA

- 6.1 Sales Volume of IBS-C Drugs in China by Major Players
- 6.2 Revenue of IBS-C Drugs in China by Major Players
- 6.3 Basic Information of IBS-C Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Players
 - 6.3.2 Employees and Revenue Level of IBS-C Drugs Major Players



- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Catalent Pharmaceuticals Solutions
 - 7.1.1 Company profile
 - 7.1.2 Representative IBS-C Drugs Product
 - 7.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent

Pharmaceuticals Solutions

- 7.2 Nestle
 - 7.2.1 Company profile
 - 7.2.2 Representative IBS-C Drugs Product
- 7.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
- 7.3 Abbott Laboratories
 - 7.3.1 Company profile
 - 7.3.2 Representative IBS-C Drugs Product
 - 7.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 7.4 Synergy Pharmaceuticals
 - 7.4.1 Company profile
 - 7.4.2 Representative IBS-C Drugs Product
 - 7.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy

Pharmaceuticals

- 7.5 Sucampo Pharmaceuticals
 - 7.5.1 Company profile
 - 7.5.2 Representative IBS-C Drugs Product
 - 7.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo

Pharmaceuticals

- 7.6 Novartis Pharma Ag
 - 7.6.1 Company profile
 - 7.6.2 Representative IBS-C Drugs Product
- 7.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
- 7.7 Astellas Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative IBS-C Drugs Product
 - 7.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas



Pharmaceuticals

- 7.8 Ardelyx, Inc
 - 7.8.1 Company profile
 - 7.8.2 Representative IBS-C Drugs Product
 - 7.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
- 7.9 Synthetic Biologics, Inc
 - 7.9.1 Company profile
 - 7.9.2 Representative IBS-C Drugs Product
 - 7.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc.
- 7.10 Teva Pharmaceutical Industries
 - 7.10.1 Company profile
 - 7.10.2 Representative IBS-C Drugs Product
- 7.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
- 7.11 Bama-Geve, SLU
 - 7.11.1 Company profile
 - 7.11.2 Representative IBS-C Drugs Product
 - 7.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
- 7.12 Ferring BV
 - 7.12.1 Company profile
 - 7.12.2 Representative IBS-C Drugs Product
 - 7.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
- 7.13 Ironwood Pharmaceuticals, Inc.
 - 7.13.1 Company profile
 - 7.13.2 Representative IBS-C Drugs Product
 - 7.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood

Pharmaceuticals, Inc

- 7.14 Salix Pharmaceuticals Ltd
 - 7.14.1 Company profile
 - 7.14.2 Representative IBS-C Drugs Product
- 7.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
- 7.15 Norgine B.V
 - 7.15.1 Company profile
 - 7.15.2 Representative IBS-C Drugs Product
 - 7.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
- 7.16 Prometheus Laboratories Inc
- 7.17 Actavis Nordic A/S
- 7.18 Albireo Pharma Inc



- 7.19 Yuhan Corp
- 7.20 Astrazeneca Plc
- 7.21 The Menarini Group
- 7.22 Ono Pharmaceutical Co., Ltd

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS

- 8.1 Industry Chain of IBS-C Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS

- 9.1 Cost Structure Analysis of IBS-C Drugs
- 9.2 Raw Materials Cost Analysis of IBS-C Drugs
- 9.3 Labor Cost Analysis of IBS-C Drugs
- 9.4 Manufacturing Expenses Analysis of IBS-C Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF IBS-C DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation



12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Reference



I would like to order

Product name: IBS-C Drugs-Asia Pacific Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/I7D0A363330MEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/I7D0A363330MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms